When Flu Hits Hard, Your Formula Has to Work Harder
As case volume rises, expectations shift. People are not simply looking for symptom relief. They need solutions that help them stay functional, recover sooner, and manage illness at home rather than escalating into costly and disruptive medical care.
Government of Canada. (2026). Respiratory virus report: Week 3 (week ending January 24, 2026). Public Health Agency of Canada. https://health-infobase.canada.ca/respiratory-virus-surveillance/
Translating Flu Burden Data Into Real-World Implications
This season is placing sustained pressure on cold and flu portfolios because demand is concentrating around multi-symptom products that can act early, work quickly, and perform reliably. When multiple symptoms present simultaneously, consumers expect a single regimen that can keep pace with real-world needs, rather than a fragmented approach.
Why multi-symptom products matter more during peak flu season?
For formulators, the implications are clear:
✅ Multi-symptom products must support fast, reliable relief early in the illness window
✅ They must be easy to take under compromised conditions [ fatigue, congestion, or nausea]
✅ They must be dependable at scale, because demand accelerates quickly
Other offerings for formulating fast-acting, scalable products:
Formulate fast-acting, scalable products:
Acetaminophen | Proven, Fast-Acting Relief
A globally trusted analgesic and antipyretic for flu symptom control.
✓ Rapid reduction of fever & pain, the symptoms most likely to drive hospital visits if unmanaged.
✓ Well-established safety profile with broad global acceptance across populations.
✓ Reliable performance at high doses
✓ Globally trusted and regulator–ready
✓ Highly compatible and formulation-flexible, enabling easy combination with other APIs across tablets, liquids, chewables, and softgels.
Sorbitol Special | Optimized Shell Performance
✓ Faster processing and drying times improve throughput without sacrificing quality.
✓ Aqueous fill compatibility and mechanical stability help reduce leakage and extend shelf life.
✓ Enhanced deliverability supports stable, uniform dosing—critical for rapid symptom relief.
Sorbitol Special provides added benefits to get your softgels out to the market faster, more stable, with more flexibility and for longer.
Migylol® 812 | Efficient Carrier for Lipophilic APIs
Enables rapid solubilization and absorption in liquid and semi-solid flu formulations.
✓ C8/C10 MCT structure supports faster uptake for quicker onset.
✓ Low viscosity and neutral taste improve swallowability when patients feel unwell.
✓ Excellent solubilization of lipophilic actives improves dose consistency and bioavailability.
✓ Formulation flexibility and stability use across softgels, liquids, and emulsions
Miglyol oils support solubilization in liquid and semi-solid formulations where speed and ease of use matter.
UltraBurst™ Platform Technology | Built for formulators ready to move beyond liquid limits
Enables rapid solubilization and absorption in liquid and semi-solid flu formulations.
✓ Quick dissolving tablet (12 seconds)
✓ Easy to consume and patient-friendly
✓ Accurate 10mg dosing for pediatric safety
✓ Eliminates DEG/EG contamination risk
✓ Improved stability vs. liquid formulation
Ultraburst is an Innovative excipient platform for ODTs. Delivering the fastest disintegration time of any preformulated products on the market
